Clinical Trial Update: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen [Phase 3]

View source ↗

Summary

Phase IIIb trial assessing safety, efficacy, and tolerability after switching virologically suppressed patients to the fixed-dose combination abacavir/dolutegra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Triumeq (dolutegravir/abacavir/lamivudine)

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus | Phase 3 | Status: COMPLETED | Results posted: 2016-02-25